^
Association details:
| Biomarker: | PTPRC expression |
|---|---|
| Cancer: | Leukemia |
| Drug: | CD45-ADC (RNA polymerase 2 inhibitor, CD45-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Development of Anti-CD45 Antibody Drug Conjugates As Targeted Conditioning Agents for Transplantation/Gene Therapy with Potent Anti-Leukemic Properties
Published date:
11/15/2022
Excerpt:
Anti-CD45 ADCs YTH24.5-SG3249 and YTH24.5-SG3376 potently and specifically killed human CD45-expressing leukemic cell lines in cell viability assays, with EC50 values of 0.213 pM and 0.052 pM, respectively...Moreover, the anti-CD45 ADCs also showed potent anti-leukemic activity and prevented the development of AML and prolonged survival (p<0.01 for both YTH24.5 ADCs vs Isotype ADC controls) in a xenogeneic OCIM1 model of AML in NSG mice...
DOI:
https://doi.org/10.1182/blood-2022-162390
